Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
pharmaphorum5h
NICE blames companies for breakdown in Enhertu talks
AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...
FiercePharma1d
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
pharmaphorum6h
MSD says subcutaneous Keytruda matches IV form
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...
Breast cancer drug blocked for NHS use as price talks break down for third time
Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the health service after ...
STAT8d
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
The Pharma Letter3h
Talks with Enhertu makers end without agreement, says the NICE
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...
FiercePharma12d
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...